Diets & Weight Loss

Subcutaneous

Beneath the skin

Question: How often should a cat recieve subcutaneous fluids for? Dehydrated cat due to illness last week so the vet gave her subcutaneous fluids. He told me to come back in 3 days. Is this normal or should she have it every day.?He says she absorbed quite a bit of fluids and left her on it for 15 minutes. At the moment she isnt drinking her own water this is why she had this type of drip.

Answer: Once every few days is fine, but every day is fine too as long as the cat is urinating OK. Subcutaneous fluids is just an alternative way for the cat to receive water when it won't drink. It also helps to push fluids through the kidneys when there are kidney issues as well. Any excess fluids the cat doesn't need for hydration will be urinated away. Depending upon whether your cat is too weak from the illness or if this is a respiratory illness, once daily may in fact be too frequent. You can always ask your vet if you should bring the cat in more frequently for fluids, would it be any more helpful than every 3 days. Most vets will be happy to explain why more frequently may be better or worse for your cat.

 


Subcutaneous Related Products and News

Baxter's Investigational 20% Subcutaneous Immunoglobulin Treatment Meets ...

Business Wire (press release)
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) presented the results of a Phase 2/3 study of its investigational 20 percent concentration subcutaneous immunoglobulin treatment for primary immunodeficiencies (PI) during the ...
 

Subcutaneous Octreotide May Offer Better Option for Managing NETS Symptoms

OncLive
NANETS A subcutaneous depot formulation of octreotide has a rapid onset, greater bioavailability, and a similar duration of effect compared with intramuscular octreotide long-acting repeatable (LAR). The pharmacokinetics and pharmacodynamics of ...
 

USA TODAY

A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned ...
CNNMoney
 

Exenatide continuous subcutaneous delivery met clinical endpoints in phase 3 ...

Healio
Exenatide delivered continuously once- or twice-yearly via an investigational matchstick-sized, subcutaneous, miniature osmotic pump designed by Intarcia Therapeutics, Inc. met HbA1c and weight reduction endpoints in two phase 3 trials, according to a ...
 

Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl ...

Business Wire (press release)
Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive results from the phase III study of triptorelin pamoate 11.25 mg (Decapeptyl® 3 months) administered subcutaneously in patients with locally advanced or metastatic prostate cancer at the ...
 

Ipsen reports positive prostate cancer data for subcutaneous Decapeptyl

Zenopa
Claude Bertrand, executive vice-president of research and development and chief scientific officer of Ipsen, said: "The subcutaneous route widens the options for the administration of Decapeptyl and may be offered to patients for whom intramuscular ...
 

Pharmaceutical Business Review

Stiefel begins phase III study of subcutaneous of atumumab in pemphigus ...
pharmabiz.com
 

Subcutaneous implant with etonogestrel (Implanon(R)) for catamenial ...

7thSpace Interactive (press release)
Cystic Fibrosis (CF) is a genetic disease with equal prevalence across sexes. However, women present worse lung function with faster function decline, earlier onset of bacterial colonization, more frequent pulmonary exacerbations (PE), greater ...
 

NeuroDerm Announces Positive Topline Results of Phase II, Placebo-Controlled ...

PR Newswire (press release)
NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that patients with moderate to severe Parkinson's disease who received continuous, subcutaneous doses of liquid ...
 

Glaxo's Stiefel Starts Phase III Study Of Subcutaneous Ofatumumab

London South East
LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday its company Stiefel has started a phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab for the treatment of autoimmune skin disorder pemphigus vulgaris. The disorder ...